IGF-1 LR3 (1 mg vial)
Once daily subcutaneous protocol for growth hormone axis research.
IGF-1 LR3 is an insulin-like growth factor analog engineered with an arginine substitution and N-terminal extension that keep it off binding proteins, making it far more potent hour for hour. That potency includes real hypoglycemia risk. The protocol below runs strict short cycles with glucose monitoring.
Quick answer: at the standard 1 mg + 1 mL reconstitution, a 50 mcg dose of IGF-1 LR3 draws 5 units (0.05 mL) on a U-100 insulin syringe, once daily subcutaneous.
Get IGF-1 LR3 → code PEPDOSE
Protocol overview
Dosing & reconstitution
Frequency: Once daily subcutaneous
Typical duration: 8 weeks on, 4-8 weeks off
Reconstitution: 1 mg vial + 1 mL bacteriostatic water = 1 mg/mL. Units below are for a U-100 insulin syringe at this concentration.
| Phase | Dose | Units per injection |
|---|---|---|
| Weeks 1-2 | 20 mcg | 2 units (0.02 mL) |
| Weeks 3-4 | 40 mcg | 4 units (0.04 mL) |
| Weeks 5-8 | 50 mcg | 5 units (0.05 mL) |
Units = (dose ÷ concentration) × 100 on a U-100 syringe. Change the vial size or water volume and the calculator redoes all of this for you.
Track this protocol → Free account · log doses, rotate sites, never lose your history
IGF-1 LR3 dosing — what the literature actually supports
We publish a schedule when there is a citable human source and we say so when there is not. Filling this space with a number nobody measured would make the page look more complete and be worth less than nothing to you.
Reconstitution and measurement
This part is arithmetic and does not depend on the evidence level. Concentration is vial size divided by the bacteriostatic water you add. Draw volume is your target amount divided by that concentration. Units are draw volume times 100, because a U-100 syringe reads 100 units per millilitre. Common vials for IGF-1 LR3: 0.1 mg (100 mcg).
- Wipe the stoppers of both vials with an alcohol swab and let them dry.
- Draw the bacteriostatic water with a sterile syringe and inject it slowly down the inside wall of the peptide vial — never straight onto the powder.
- Swirl gently until the solution is clear. Do not shake; foaming and agitation damage peptides.
- Label the vial with the date and concentration, and refrigerate at 2–8 °C protected from light.
Worked example at the calculator defaults: 0.1 mg + 1 mL of bacteriostatic water = 0.1 mg/mL, so on a U-100 insulin syringe 1 unit = 1 mcg of IGF-1 LR3. Change either input and the calculator redoes this for you.
Storage and stability
Supplies math
Whatever amounts your research uses, the planning arithmetic is the same. The calculator runs all of this per compound.
Supplies by protocol length
Based on the maintenance dose above (50 mcg, once daily subcutaneous) and a 1 mg vial reconstituted with 1 mL.
| Duration | Injections | Vials | Syringes | Bac water | Swabs |
|---|---|---|---|---|---|
| 8 weeks | 56 | 3 x 1 mg | 62 | 1 x 10 mL | 112 |
| 12 weeks | 84 | 5 x 1 mg | 93 | 1 x 10 mL | 168 |
| 16 weeks | 112 | 6 x 1 mg | 124 | 1 x 10 mL | 224 |
Syringe count includes ~10% spares. Swabs = 2 per injection (stopper + site). Vial count assumes the full maintenance dose for the entire duration.
Important notes
Practical considerations for consistency and safety.
- Use a new sterile insulin syringe for each injection and dispose in a proper sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and avoid lipohypertrophy.
- Inject slowly and steadily; wait a few seconds before withdrawing the needle to ensure complete delivery.
- Administer at the same time each day for consistent levels. Setting a daily reminder helps maintain the schedule.
- This compound lacks controlled human safety data. Start with the lowest reported amount and increase gradually while monitoring for any adverse reactions.
- The 1 mg vial size is standard for this compound. Reconstitute with 1 mL bacteriostatic water for a convenient concentration.
How IGF-1 LR3 works
An IGF-1 analog with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. Those changes sharply reduce binding to IGF binding proteins, leaving more of it free and active — which is also why it is more potent than native IGF-1.
Benefits & side effects
Potential benefits
- Extended half-life IGF-1 analog
- Potent anabolic and recovery support
- Direct action without needing GH conversion
- Supports muscle growth and repair
Possible side effects
- Hypoglycaemia risk (potent insulin-like activity)
- Joint pain
- Must cycle strictly with time off
- Monitor blood glucose carefully
This list reflects published literature and community reports. Individual responses vary. Not medical advice.
Bloodwork worth tracking
The community-standard practice is a baseline panel before starting, a recheck 8 to 12 weeks in, and another after time off. For IGF-1 LR3, the markers most worth watching:
IGF-1fasting glucoseHbA1clipid panel
Typical time off: 4-8 wks
Lab panels are how a research protocol stays honest: numbers move before symptoms do. Interpretation belongs with a clinician. Not medical advice.
Lifestyle factors
None of the literature above was run on a background of poor sleep and no protein. These variables move outcomes more reliably than any compound on this site.
- Protein in the 1.6 to 2.2 g/kg range preserves lean mass through any body-composition phase.
- Resistance training 2 to 4 days per week plus 150+ minutes of weekly aerobic work reinforces whatever the protocol is doing.
- Sleep is the recovery window: 7 to 9 hours at consistent times.
- Hydration matters more than usual on compounds with GI or flushing effects: 2 to 3 liters daily.
- Track the variables that matter: weigh-ins, measurements, photos, and labs at sensible intervals.
Subcutaneous technique and practical notes
General best practice from clinical injection guidance — the same fundamentals nurses are taught, none of it specific to any compound.
Quick answers
How many syringe units is a 50 mcg dose of IGF-1 LR3?
At the standard reconstitution of 1 mg with 1 mL bacteriostatic water (1 mg/mL), a 50 mcg dose draws 5 units (0.05 mL) on a U-100 insulin syringe.
How do you reconstitute IGF-1 LR3?
Add 1 mL of bacteriostatic water to the 1 mg vial for 1 mg/mL. Inject the water slowly down the inside wall of the vial, swirl gently without shaking, and refrigerate at 2 to 8 °C after mixing.
How long does a 1 mg vial of IGF-1 LR3 last?
About 20 maintenance doses of 50 mcg, roughly 2.9 weeks at once daily subcutaneous.
Does IGF-1 LR3 have human trial data?
No. The evidence base is animal and cell studies; the practical dosing shown is community convention, and the page labels it that way.
How does IGF-1 LR3 work?
An IGF-1 analog with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. Those changes sharply reduce binding to IGF binding proteins, leaving more of it free and active — which is also why it is more potent than native IGF-1.
Sourcing IGF-1 LR3
Whatever you are working with, the documentation matters more than the price. Ask for a batch certificate of analysis whose lot number matches the vial you actually receive — a COA for a different batch tells you nothing about yours.
IGF-1 LR3 at Summit Research Supply → Grade a COA first
Summit is the supplier we feature and an affiliate link. Our COA checklist applies the same way to any vendor.
